IO | Jotup

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Retrieved on:

måndag, juni 3, 2024

Nature, IHC, Aes, Asthma, Histology, ASCO, RECIST, Pharmacology, IO, Ovarian cancer, Fatigue, Patient, Dermatitis, AACR, Annual general meeting, Cancer, Genetics, Safety, Society, Ascites, Psoriasis, Therapy, PR, Genome, Risk, CD200, Death, Neoplasm, Itch, Signature, Nausea, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4.

Key Points:

23andMe presented two posters on 23ME-00610, one each from neuroendocrine and ovarian cancer patient cohorts in its ongoing Phase 1/2a clinical trial.
23ME-00610 monotherapy demonstrates acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks.
In addition to CD200, histology data suggest that immunosuppressed (“cold”) tumors may be more likely to exhibit disease control with 23ME-00610.
Patients received 1400 mg given IV every 3 weeks until disease progression, and CT/MRI scans were conducted every ~ 8 weeks.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Retrieved on:

söndag, juni 2, 2024

Cancer, IO, Interim, CD137, Glioblastoma, Liver, PD-L1, Patient, Annual general meeting, NSCLC, Immunotherapy, Society, Pembrolizumab, Sarcoma, Head, Stomach, Lung cancer, PRS, RDE

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.

Key Points:

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024.
“MCLA-145 as monotherapy or with pembrolizumab appears to have a manageable safety profile and early clinical activity in these difficult to treat cancers.
Pts treated with the combination of MCLA-145 and pembrolizumab had cancers that either relapsed after PD-(L)1 therapies or were immunotherapy (IO) naïve.
per investigator assessment
MCLA-145 monotherapy or in combination with pembrolizumab had a well-tolerated and manageable safety profile at the RDE, 40mg Q3W
Liver toxicity, a common CD137 related adverse event, was controlled with no G4 events observed at Q3W

Redpanda Acquires Benthos to Deliver a Complete, End-to-End Streaming Data Platform

Retrieved on:

torsdag, maj 30, 2024

Streaming data pioneer Redpanda today announced its acquisition of London-based Benthos, the popular open-source stream processing platform that enables enterprises to move, integrate, and perform transformations on streams of data flowing between systems and data sources.

Key Points:

Streaming data pioneer Redpanda today announced its acquisition of London-based Benthos, the popular open-source stream processing platform that enables enterprises to move, integrate, and perform transformations on streams of data flowing between systems and data sources.
It lets engineers quickly build connectivity to streaming sources, transforming data pipelines to power real-time data products.
With Redpanda Connect, the Redpanda streaming data platform easily connects with a wealth of AI systems, databases, data warehouses, applications and files to streamline and simplify the creation of composable data products.
"Redpanda Connect with Ockam is the world’s first end-to-end, zero-trust streaming data platform," said Matthew Gregory, Ockam’s CEO.

KBRA Assigns Preliminary Ratings to J.P. Morgan Mortgage Trust 2024-HE2 (JPMMT 2024-HE2)

Retrieved on:

onsdag, maj 29, 2024

Banking, Professional Services, Finance, RMBS, United Wholesale Mortgage, FOCUS, IO, HELOC, J. P. Morgan, KBRA, Telescopic sight

KBRA assigns preliminary ratings to 7 classes of Mortgage Participation Pass-Through Certificates from J.P. Morgan Mortgage Trust 2024-HE2 (JPMMT 2024-HE2), a $379.9 million RMBS transaction sponsored by J.P. Morgan Mortgage Acquisition Corp. (J.P. Morgan) and FOCUS III Advisory, LLC (FOCUS) consisting entirely of second lien home equity line of credit (HELOC) loans.

Key Points:

KBRA assigns preliminary ratings to 7 classes of Mortgage Participation Pass-Through Certificates from J.P. Morgan Mortgage Trust 2024-HE2 (JPMMT 2024-HE2), a $379.9 million RMBS transaction sponsored by J.P. Morgan Mortgage Acquisition Corp. (J.P. Morgan) and FOCUS III Advisory, LLC (FOCUS) consisting entirely of second lien home equity line of credit (HELOC) loans.
The underlying pool is seasoned approximately three months and comprises of 4,321 loans, with United Wholesale Mortgage, LLC (68.4%) and loanDepot.com, LLC (19.3%) representing the largest contributing originators.
The HELOCs are interest-only (IO) adjustable-rate mortgages, with IO terms of mostly ten years (97.8%).
Most of the loans feature 20-year (95.5%) amortization terms, and HELOC initial draw windows of three (86.5%) or ten (12.3%) years.

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

torsdag, maj 23, 2024

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

Key Points:

“The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline.
Abstract # 2664: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.
Preliminary results and acceptable safety profile support further evaluation of CHS-114 in combination treatment with toripalimab and other I-O agents.
In 19 patients evaluable for response, no objective responses were yet noted, while the stable disease rate was 47%.

POET Technologies Reports First Quarter 2024 Financial Results

Retrieved on:

onsdag, maj 15, 2024

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its unaudited condensed consolidated financial results as of and for the three months ended March 31, 2024.

Key Points:

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its unaudited condensed consolidated financial results as of and for the three months ended March 31, 2024.
Non-cash expenses in the first quarter of 2024 included stock-based compensation of $0.9 million and depreciation and amortization of $0.5 million.
Cash flow from operating activities in the first quarter of 2024 was ($4.6) million, compared to ($3.6) million in the first quarter of 2023 and ($2.9) million in the fourth quarter of 2023.
These non-IFRS financial performance measures are included because management has used the information to analyze the business performance and financial position of POET.

IO Interactive Welcomes Ulas Karademir as New Chief Technology Officer

Retrieved on:

onsdag, maj 15, 2024

Entertainment, Consumer Electronics, Technology, Software, Electronic Games, Hardware, IOI, IO Interactive, Véronique, Contract killing, Engineering, CPO, Knowledge, Multimedia, IO, Video game

IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Ulas Karademir will be joining IOI as its new Chief Technology Officer, reporting to IOI’s CEO, Hakan Abrak.

Key Points:

IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Ulas Karademir will be joining IOI as its new Chief Technology Officer, reporting to IOI’s CEO, Hakan Abrak.
View the full release here: https://www.businesswire.com/news/home/20240513208152/en/
Ulas is a familiar face at IO Interactive, having worked there for more than seven years between 2007 and 2014.
Ulas Karademir’s arrival is the latest of IO Interactive's appointments among its leadership, with Veronique Lallier having joined as its Chief Development Officer last January and Olivier Perbet as its Chief Marketing Officer last year.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Retrieved on:

fredag, maj 10, 2024

“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.

Key Points:

“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.
The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity.
Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells.
As CMO, Pejvack will drive the clinical and medical strategy and development of our Company in the years to come.

Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

Retrieved on:

torsdag, maj 9, 2024

Corporation, FDA, TFX, Research, Workflow, IO, Health, Emergency medicine, Vascular access, Medical imaging

WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray.

Key Points:

WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray.
This sterile, single-use tray includes all the components required for the IO access procedure, enabling a streamlined clinician workflow.
The tray is packaged with an Arrow™ EZ-IO™ Intraosseous Needle Set (15mm, 25mm, or 45mm), which is designed to help ensure a fast,1 precise, and steady insertion.
“The new Arrow™ EZ-IO™ Procedure Tray was designed to optimize efficiency in gaining fast vascular access while increasing the accessibility of the EZ-IO™ System,” said Kevin Robinson, President and General Manager of Anesthesia and Emergency Medicine, Teleflex.

PDRI Releases Virtual Interview Tool on its Palladium Assessment Platform to Enable Structured Interviews

Retrieved on:

onsdag, maj 8, 2024

Interview, Intuition, Meta-analysis, Bias, Research, FedRAMP, Government, Psychology, Privacy, IO, Workforce, Private sector, Risk assessment, Organization, PDRI

ARLINGTON, Va., May 8, 2024 /PRNewswire/ -- PDRI by Pearson (FTSE: PSON.L), a workforce assessment provider that transforms evidence-based insights into talent management solutions, today announced the launch of a virtual interview tool for its Palladium assessment platform.

Key Points:

ARLINGTON, Va., May 8, 2024 /PRNewswire/ -- PDRI by Pearson (FTSE: PSON.L), a workforce assessment provider that transforms evidence-based insights into talent management solutions, today announced the launch of a virtual interview tool for its Palladium assessment platform .
Interviews are ubiquitous in hiring processes, but most are unstructured, and research shows that unstructured interviews have low validity and a great potential for bias.
PDRI's new interview tool helps organizations make accurate and unbiased talent decisions and saves time and valuable resources."
PDRI's virtual interview tool is now available to private sector and government clients as a standalone offering or part of a seamless larger assessment experience.